共 50 条
- [1] IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablationONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 239 - 239Trojan, J.Chow, P.Chen, M.Cheng, A-LKaseb, A.Kudo, M.Lee, H. C.Yopp, A.Zhou, J.Wang, L.Wen, X.Heo, J.Tak, W-YNakamura, S.Numata, K.Uguen, T.Hsieh, D.Cha, E.Hack, S. P.Lian, Q.Spahn, J.Wu, C.Qin, S.
- [2] IMbrave050: Efficacy, safety and patient-reported outcomes (PROs) for adjuvant atezolizumab (atezo) plus bevacizumab (bev) vs active surveillance in hepatocellular carcinoma (HCC) patients at high risk of disease recurrence after resection or ablationJOURNAL OF HEPATOLOGY, 2023, 78 : S9 - S10Kaseb, AhmedChen, MinshanChow, PierceKudo, MasatoshiLee, Han ChuYopp, AdamBecker, LarsHernandez, SairyKovic, BrunoLian, QinshuMa, NingWu, ChunQin, ShukuiCheng, Ann-Lii
- [3] Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) plus bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablationJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Kudo, MasatoshiChen, MinshanChow, Pierce K. H.Kaseb, Ahmed OmarLee, Han ChuYopp, Adam C.Becker, LarsPainter, Sairy HernandezKovic, BrunoLian, QinshuMa, NingWu, ChunQin, ShukuiCheng, Ann-Lii
- [4] IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablationFUTURE ONCOLOGY, 2020, 16 (15) : 975 - 989Hack, Stephen P.Spahn, JessicaChen, MinshanCheng, Ann-LiiKaseb, AhmedKudo, MasatoshiLee, Han ChuYopp, AdamChow, PierceQin, Shukui
- [5] Updated efficacy and safety data from IMbrave050: Phase III study of adjuvant atezolizumab (atezo) plus bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)ANNALS OF ONCOLOGY, 2024, 35 : 1230 - 1230Yopp, A.Kudo, M.Chen, M.Cheng, A-L.Kaseb, A. O.Lee, H. C.Qin, S.Cha, E.Hack, S. P.Lian, Q.Spahn, J.Wu, C.Chow, P.
- [6] Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trialLANCET, 2023, 402 (10415): : 1835 - 1847Qin, ShukuiChen, MinshanCheng, Ann-LiiKaseb, AhmedKudo, MasatoshiLee, Han ChuYopp, Adam C.Zhou, JianWang, LuWen, XiaoyuHeo, JeongTak, Won YoungNakamura, ShinichiroNumata, KazushiUguen, ThomasHsiehchen, DavidCha, EdwardHack, Stephen P.Lian, QinshuMa, NingSpahn, Jessica H.Wang, YuleiWu, ChunChow, Pierce K. H.
- [8] COMPARISON OF RECURRENCE PREDICTION MODELS AND IMBRAVE 050 CRITERIA TO SELECT PATIENTS FOR ADJUVANT IMMUNOTHERAPY AFTER CURATIVE RESECTION OF HEPATOCELLULAR CARCINOMAHEPATOLOGY, 2023, 78 : S92 - S92Lee, I-ChengChu, Hao-CyuanHo, Shinn-YingChau, Gar-YangHou, Ming-ChihHuang, Yi-Hsiang
- [9] A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after curative hepatic resection or ablation: EMERALD-2ANNALS OF ONCOLOGY, 2019, 30Knox, J.Cheng, A.Cleary, S.Galle, P.Kokudo, N.Lencioni, P.Park, J.Zhou, J.Mann, H.Morgan, S.Liu, X.Chin, S.Vlahovic, G.Fan, J.
- [10] Atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma: The randomised phase III study IMbrave150ANNALS OF ONCOLOGY, 2018, 29 : 267 - 267Ducreux, M. P.Cheng, A-L.Qin, S.Zhu, A. X.Ikeda, M.Kim, T-Y.Xu, D-Z.Verret, W.Liu, J.Finn, R. S.Galle, P. R.